Published in J Gastroenterol on May 01, 2005
A glass of water immediately increases gastric pH in healthy subjects. Dig Dis Sci (2008) 0.88
A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. J Gastroenterol (2010) 0.82
Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison. J Clin Biochem Nutr (2014) 0.82
Early effects of oral administration of omeprazole and roxatidine on intragastric pH. J Zhejiang Univ Sci B (2012) 0.81
Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial. Gastroenterol Res Pract (2011) 0.80
Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection. World J Gastroenterol (2007) 0.80
Is oral combination therapy with a proton-pump inhibitor and H2 receptor antagonist effective as initial treatment? J Gastroenterol (2007) 0.79
Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole. World J Gastroenterol (2008) 0.79
Early effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values. BMC Gastroenterol (2009) 0.79
A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting? J Gastroenterol (2005) 0.78
Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial. Dig Dis Sci (2014) 0.75
Early effect of oral administration of omeprazole with mosapride as compared with those of omeprazole alone on the intragastric pH. BMC Gastroenterol (2012) 0.75
An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition. World J Gastrointest Pharmacol Ther (2010) 0.75
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology (2003) 2.65
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients. Clin Gastroenterol Hepatol (2011) 2.44
Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion (2009) 2.43
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol (2007) 2.29
Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc (2007) 2.23
FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res (2007) 2.21
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res (2010) 2.20
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A (2006) 2.17
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther (2007) 2.12
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res (2007) 2.10
Variations in the FTO gene are associated with severe obesity in the Japanese. J Hum Genet (2008) 2.03
A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology (2003) 1.91
An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (2005) 1.86
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) (2010) 1.86
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res (2006) 1.78
Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology (2010) 1.71
Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm. Surg Endosc (2010) 1.70
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog (2010) 1.69
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol (2009) 1.69
Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci (2008) 1.69
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res (2012) 1.66
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther (2011) 1.66
Contrast-enhanced sonography of pancreatic carcinoma: correlations with pathological findings. J Gastroenterol (2005) 1.65
Ly6C+ Ly6G- Myeloid-derived suppressor cells play a critical role in the resolution of acute inflammation and the subsequent tissue repair process after spinal cord injury. J Neurochem (2013) 1.60
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A (2009) 1.56
Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun (2007) 1.55
Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res (2007) 1.55
The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. J Gastroenterol (2004) 1.52
A cross-sectional study on the risk factors for erosive esophagitis in young adults. Intern Med (2012) 1.52
CDH13 Polymorphisms are Associated with Adiponectin Levels and Metabolic Syndrome Traits Independently of Visceral Fat Mass. J Atheroscler Thromb (2015) 1.50
Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab (2012) 1.50
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell (2012) 1.49
Is it worthwhile to perform capsule endoscopy for asymptomatic patients with positive immunochemical faecal occult blood test? Dig Dis Sci (2011) 1.46
Lichtheim 2: synthesizing aphasia and the neural basis of language in a neurocomputational model of the dual dorsal-ventral language pathways. Neuron (2011) 1.42
Inflammatory fibroid polyps of the stomach and Helicobacter pylori. J Gastroenterol Hepatol (2004) 1.40
Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology (2009) 1.39
Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J Biol Chem (2006) 1.39
Hemolytic episode following an upper gastrointestinal endoscopy in a patient with paroxysmal nocturnal hemoglobinuria. Dig Endosc (2011) 1.37
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis (2002) 1.35
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology (2006) 1.34
A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res (2009) 1.34
SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity (2006) 1.33
HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest (2013) 1.32
Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J (2006) 1.31
The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol (2002) 1.30
Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut (2007) 1.29
Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut (2011) 1.28
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res (2012) 1.27
Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol (2007) 1.27
Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest (2007) 1.26
The collagen-binding protein of Streptococcus mutans is involved in haemorrhagic stroke. Nat Commun (2011) 1.25
Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci (2007) 1.24
Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer (2006) 1.24
Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet (2013) 1.24
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res (2006) 1.23
Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol (2009) 1.22